anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Shampoo and shaving compositions comprise a suitable carrier in which is incorporated pelargonic acid or a salt thereof, and a perfume capable of being fixed in the carrier by the pelargonic compound. Specified pelargonate salts are sodium, potassium, lithium, ammonium and triethanolamine pelargonate.  Suitable perfumes are the essential oils: Rosedamai Absolute, Geranium Bourbon and Oil of Cordamon; synthetic aromatics: Geraniol pure, Hydroxy citronellol; compound perfume oils: lilac type, floral type or rose character.  In examples (a) a lather type shaving cream comprises stearic acid, coconut oil, potassium hydroxide, sodium hydroxide, glycerol, stearin, sodium pelargonate, Oil of Cordamon and water (b) a brushless type shaving cream comprises stearic acid, mineral oil, lanolin, gums and thickeners, sodium pelargonate, Oil of Cordamon and water (c) a brushless type shaving cream comprises stearic acid, cetyl alcohol, petrolatum, methyl p-hydroxybenzoate, lanolin, Span &#34;20&#34; (Registered Trade Mark), (i.e. sorbitan monolaurate), Tween &#34;20&#34; (Registered Trade Mark), (i.e. polyoxyethylene sorbitan monolaurate), sodium pelargonate, hydroxy citronellol and water (d) a liquid shampoo comprises sodium pelargonate, coconut oil, olive oil, castor oil, potassium hydroxide, glycerol, ethyl alcohol, sodium hexametaphosphate, Oil of Cordamon and water.ALSO:A perfumed therapeutic composition for topical application, having bacteriostatic and fungistatic properties, comprises a suitable carrier in which is incorporated pelargonic acid or a salt thereof, and a perfume capable of being fixed in the carrier by said pelargonic compound.  Specified pelargonate salts are sodium, potassium, lithium, ammonium and triethanolamine pelargonate. Suitable perfumes are the essential oils: Rosedamai Absolute, Geranium Bourbon and Oil of Cordamon; synthetic aromatics: Geraniol pure, Hydroxycitronellol; compound perfume oils: lilac type, floral type or rose character.  The compositions may be in various forms, e.g. shaving creams, shampoos antiseptic ointments, antiseptic cleansing and lubricating creams, antiseptic solutions, and hair tonics.
PROBLEM TO BE SOLVED: To obtain the subject new compound having an aryloxyacetyl group as a modifying group bonding to a terminal amino group, exhibiting excellent human immunodeficient virus protease-inhibitory activity and useful as an anti- AIDS agent. SOLUTION: This compound is expressed by the formula I (A is OCH2 CO; R1 to R5 are each H, amino, etc.; R6 is a bivalent hydrocarbon group forming a 5 to 7-membered ring together with bonding N atom and C atom or a bivalent group produced by substituting the C atom bonded to the bivalent hydrocarbon group with a hetero atom; R, is a univalent group derived from a 1-6C aliphatic hydrocarbon or a monocyclic aromatic hydrocarbon group having a total carbon number of &lt;=12), e.g. (R)-N-t-butyl-3-[(2S,3S)-2-hydroxy-3[phenoxyacetyl] amino-4- phenylbutanoyl]-1,3thiazolidine-4-carboxamide. The compound can be produced by reacting an intermediate of the formula II with an activated derivative of a carboxylic acid of the formula III (Y is a group derived from an acid anhydride, etc.).
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an improver for deterioration in production of a TGF (transforming growth factor)-β receptor with ultraviolet light and an improver for deterioration in production of collagen with the ultraviolet light improving the deterioration in production of the TGF-β receptor with the ultraviolet light, preventing the deterioration in production of the collagen and thereby carrying out prophylaxis and improvement of the formation of wrinkles or deterioration in elasticity and to provide an anti-aging external preparation for skin.  &lt;P&gt;SOLUTION: The improver for the deterioration in production of the TGF-β receptor with the ultraviolet light and improver for deterioration in production of the collagen with the ultraviolet light are characterized as comprising a cultured product of Zymomonas mobilis. The anti-aging external preparation for skin is characterized as comprising the cultured product of the Zymomonas mobilis and a hybrid cell extract from Luffa cylindrica M. Roemen and Gynostemma pentaphyllum. The reduction in the amount of the collagen produced is prevented and the prophylaxis and improvement of the formation of the wrinkles or deterioration in the elasticity found in photo-aged skin are carried out by suppressing the deterioration in production of the TGF-β receptor with the ultraviolet light. Furthermore, the formation of the wrinkles and deterioration in the elasticity are prevented and improved by using the cultured product of the Zymomonas mobilis and a hybrid cell extract from the Luffa cylindrica M. Roemen and Gynostemma pentaphyllum in combination.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE:To provide the filler of restorative dental material, having excellent surface smoothness, high surface hardness, low thermal expansion coefficient, and improved compression strength and flexural strength, by treating the surface of a vinyl polymer containing a specific inorganic oxide with a specific acid halide compound. CONSTITUTION:The objective filler is produced by compounding (A) a vinyl polymer with (B) preferably 50-90wt% spherical inorganic oxide composed mainly of silica and the oxide of metal selected from the I , II, III and IV groups of the periodic table and capable of forming a bond with silica, and having particle diameter of 0.1-1.0mum, and preferably the standard deviation of the particle size distribution of &lt;=1.30, and treating the surface of the polymer composition with (C) an acid halide compound (preferably acid chloride compound) having ethylenic unsaturated bond, e.g. methacryloyl chloride. The amount of the acid halide compound is preferably 0.1-10pts.wt. per 100pts.wt. of the filler.
PURPOSE:To provide a diagnostic composed of an antinuclear antibody labeled with radioisotope and useful for the imaging diagnosis of cancer. CONSTITUTION:A diagnostic composed of an antinuclear antibody labeled with a radioisotope (e.g. &lt;99m&gt;Tc, &lt;123&gt;I, &lt;131&gt;I, etc.). A remarkable progress in the imaging diagnosis with radioisotope has been achieved by the use of a monoclonal antibody, and the imaging diagnosis of cancer is being attempted by using a cancer- specific monoclonal antibody. However, it is necessary to prepare various kinds of monoclonal antibodies according to the kind of cancer, and there occurs the problems of specificity taking account of the heterogeneity of cancer antigen, antigen modulation, masking of cancer antigen, etc., and accordingly, the accurate diagnosis is difficult. Imaging diagnosis of cancer can be carried out by labeling an antinuclear antibody with a radioisotope since an antinuclear antibody is not accumulated in a normal tissue but accumulated in a necrotic tissue of cancer. The diagnostic is administered parenterally in a dose of about &lt;=60mCi.
Sealed, ingestible soft capsules possessing good barrier properties, and which are suitable for the delivery of therapeutic or nutritional preparations, are constructed from materials obtained from non-animal sources. The soft capsule wall is preferably a multilayered film construction comprising a layer of (I) plasticised hydroxypropyl methyl cellulose (HPMC); (ii) propylene glycol alginate (PAG) and, optionally, (iii) sodium alginate (SA) (see Figure 2, not shown). The HMPC layer is preferably the innermost layer of the multilayered wall construction. The purpose of the PAG layer is to promote adhesion. The most preferred construction comprises an innermost plasticised HMPC layer, an intermediate PAG layer and an outermost SA layer. Alternatively, the capsule wall may be formed form a layer of HMPC coated after formation with gum arabic. It is also possible to form the film layer from a blend of components, for example, a blend of 2 parts HMPC and 1 part PAG may be used to form the innermost layer of the capsule wall, or a blend of 1 part PAG and 1 part HMPC may be used to promote adhesion between the innermost HMPC and outermost SA layers. The film layers used to form the soft capsule wall should be capable of forming and/or sealing using techniques such as vacuum forming or sealing by means of radio frequency, ultrasonics or heat. The sealing properties of the capsule may be improved during its construction by the application of an alcohol such as a glycol, &lt;I&gt;e.g&lt;/I&gt;., propylene glycol, a lactone, an acetin, or a pyrrolidone to the film surface being coated.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a membrane-penetrating receptor, more particularly, an endogenous human orphan G protein coupled receptor.  &lt;P&gt;SOLUTION: This invention provides a G protein coupled receptor ([GPCR]) encoded by a cDNA comprising a specified base sequence, a plasmid comprising a cDNA comprising a specified base sequence, and a host cell comprising the plasmid. As regards the identification of the human GPCRs, some of the disclosed endogenous human GPCRs are identified according to the reinvestigation of the GenBank database information. The other disclosed endogenous human GPCRs are identified by carrying out the BLAST search of the EST database (dbsest) using specified EST clones as query sequences. Thereafter, a human genome library is screened by using the identified specified EST clones as probes.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
1. A compound having the formula: wherein R&lt;1&gt; is selected from the group consisting of halogen, preferably fluorine, C1-4alkyl, C1-4alkylthio, C1-4alkylsulfinyl and C1-4alkylsulfonyl; R&lt;2&gt; is selected from the group consisting of hydrogen, and lower alkyl; R&lt;3&gt; is selected from the group consisting of chlorine, lower alkyl, formyl and a cyano group or pharmaceutically acceptable salts thereof. 2. A compound of Claim 1, or pharmaceutically acceptable salt thereof, wherein R&lt;2&gt; is hydrogen. 3. A compound of Claim 1, or pharmaceutically acceptable salt thereof, selected from the group consisting of: or pharmaceutically acceptable salts thereof. 4. A compound of Claim 1, or pharmaceutically acceptable salt thereof of the formula: 5. A compound of Claim 1, or pharmaceutically acceptable salt thereof of the formula: 6. A compound of Claim 1, or pharmaceutically acceptable salt thereof of the formula: 7. A compound of Claim 1, or pharmaceutically acceptable salt thereof of the formula: 8. A compound of Claim 1, or pharmaceutically acceptable salt thereof of the formula: 9. An oral pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier. 10. An intravenous pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier. 11. A method for inhibiting thrombin in blood comprising adding to the blood a composition of Claim 10. 12. A method for inhibiting formation of blood platelet aggregates in blood comprising adding to the blood a composition of Claim 10. 13. A method for inhibiting thrombus formation in blood comprising adding to the blood a composition of Claim 10. 14. A method for inhibiting thrombus formation in blood comprising adding to the blood a compound of Claim 1 with a fibrinogen receptor antagonist. 15. The use of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inhibiting thrombin, inhibiting thrombus formation, treating thrombus formation, or preventing thrombus formation in a mammal. 16. A method for treating or preventing venous thromboembolism and pulmonary embolism in a mammal comprising administering to the mammal a composition of Claim 10. 17. A method for treating or preventing deep vein thrombosis in a mammal comprising administering to the mammal a composition of Claim 10. 18. A method for treating or preventing cardiogenic thromboembolism in a mammal comprising administering to the mammal a composition of Claim 10. 19. A method for treating or preventing thromboembolic stroke in humans and other mammals comprising administering to the mammal a composition of Claim 10. 20. A method for treating or preventing thrombosis associated with cancer and cancer chemotherapy in a mammal comprising administering to the mammal a composition of Claim 10. 21. A method for treating or preventing unstable angina in a mammal comprising administering to the mammal a composition of Claim 10.
PURPOSE:To obtain a remedy for athlete&#39;s foot which can completely cure the disease in a short period, even when it is severe, by using leaf tobacco, shred tobacco or extract of tobacco with water. CONSTITUTION:The drug is made of leaves or stems of tobacco, shred tobacco or extract of tobacco leaves such as supernatant. When the leaf or stem is used as such, it is applied to the affected part and pressed with an adhesive tape or the like (this treatment is suitable for wet-type athlete&#39;s foot). When the extract is used, the affected part is immersed in it or it is applied to the affected part. The application of the remedy can cure athlete&#39;s foot in a short term, even when it is heavy regardless of wet or dry type. The side-effect such as inflammation of skin does not take place at all.
PURPOSE:To provide a chemical embolization treatment agent composed of a coarse crystal of a hardly soluble carcinostatic agent having an average particle diameter falling within a specific range and exhibiting activated physical and chemical properties of the single carcinostatic agent without using a raw material for drug preparation. CONSTITUTION:The objective agent for chemical embolization treatment is composed of coarse crystals of a hardly soluble carcinostatic agent (e.g. platinum complex compound, epoxide or adriamycin) having an average particle diameter of 10-1,500mum, especially 50-800mum and a water-solubility of &lt;=5wt.%, especially &lt;=1wt.% at 37 deg.C. Said coarse crystalc an be prepared by growing a crystal spending a long period by spontaneous cooling or keeping at or above the room temperature (20 deg.C or above) in recrystallization. The fraction of the crystalline state of the coarse crystal exhibits the embolization effect in a living tissue and the dissolved fraction exhibits the carcinostatic action. The agent acts as a chemical embolizaiton treatment agent by the competitive action of both fractions.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a cosmetic product effective for further improving the UV-protecting action of titanium dioxide.  &lt;P&gt;SOLUTION: (1) A clay mineral modified with an organic material and (2) fibrous titanium dioxide are included in a cosmetic product. The clay mineral modified with an organic material is preferably hectorite modified with dimethyl distearyl ammonium chloride and the fibrous titanium dioxide preferably has a hollow tubular form. The cosmetic product preferably contains phenoxyethanol and is preferably free from butylparaben. The cosmetic product is preferably summer season cosmetics.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a cell growth promoter and a skin care preparation for external use comprising an extract from a nostoc.  &lt;P&gt;SOLUTION: The cell growth promoter and the skin care preparation for external use comprise the extract from the nostoc. The nostoc used herein is a terrestrial alga of the genus Nostoc. Nostoc commune Vauch. var. flagelliforme, Nostoc commune Vauch., or the like, are cited.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To inhibit cognitive deterioration in adults with Down syndrome.  &lt;P&gt;SOLUTION: The present invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents inhibiting the binding of cortisol to its receptors can be used in methods for preventing or reversing cognitive deterioration in adults with Down syndrome. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The present invention also provides a kit for preventing or reversing cognitive deterioration in a DS patient including a glucocorticoid receptor antagonist and instructional material teaching the adaptation syndrome, dosage and schedule of administration of the glucocorticoid receptor antagonist.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To provide a pharmaceutical composition that contains a specific polyalkylene glycol, water, an effective amount of gelling agent, and includes a substantially translucent gel filler that is useful for producing soft gelatin capsules and contains pharmaceuticals in the gel. SOLUTION: The filling agent for soft gelatin capsules contains polyalkylene glycol with an average molecular weight of about &lt;=600, water and an glycol- gelling effective amount of a gelling agent. In addition, an effective amount of medicine is dissolved or suspended in this gel to give the pharmaceutical composition that has the turbidity of about 1,300 NTu. The medicines used here is, for example, acetaminophen, famotidine or chlorpheniramine. The gelling agent is, for example, sodium stearate. The gel filler is preferably composed of about 35-95 wt.% of polyethylene glycol, about 5-25 wt.% of water and 0.25-5 wt.% of the gelling agent. This gel has too high a viscosity to be injected with a syringe (needle less than 18 gage) at a room temperature.
A contact tracing system and method identifies which persons at a facility may have been exposed to a possibly contagious person. In some examples, multiple sensors, such as access card readers and cameras with video and thermographic imaging, monitor individuals at the facility. For each person, the system collects data pertaining to an individual&#39;s location and/or temperature at discrete points in time. In addition to collecting data throughout the day, data is also collected over an extended period of days or weeks. Based on data recorded during the extended periods, the system determines each person&#39;s typical schedule and travel pattern through the facility. When one or more sensors detect a possibly contagious person by sensing a fever, or even a gradually rising body temperature, the system searches for person&#39;s whose typical schedule and travel patterns overlap with those of the contagious person. The system then automatically notifies people accordingly.
FIELD: medicine. ^ SUBSTANCE: invention concerns medicine. The polymeric particles containing active substance for release of active substances, containing vinyl polymerisation product from 10-80 wt % are described; containing amino - and-or carboxyl groups of monomers, 20-90 wt % of compound alkyl ethers of acrylic and-or methacrylic acids which is insoluble in a part of pH in 0-10 range and soluble in other part of the range, and these polymeric particles containing active substance in the form of water dispersion - contain 3-1000 parts of active substance per one part of vinyl polymerisation product, - have the size of particles in a range of 20 nanometers - 8 microns and - vinyl polymerisation product on &gt;50 wt % is constructed of polymers with molecular weight &lt;100.000 dalton. The invention is referred on the aimed release of liquid active substances. ^ EFFECT: provision of aimed release of liquid operating substances. ^ 7 cl, 5 ex
ABSTRACT OF THE DISCLOSURE Compounds are described of the general formula:                     wherein:          R1 is acyl of the formula -C(=O)-R5; R2, R3, R4, R6, R7 and R8 are each selected from the group consisting of hydrogen and acyl of the formula:                     -C(=O)-R5 wherein R5 is selected from the group consisting of alkyls, substituted alkyls, alkenyls, substituted alkenyls, cycloalkyls, substituted cycloalkyls, arylalkylenes, substituted arylalkylenes, alkylenecycloalkyls, alkylene substituted cycloalkyls, alkynyls, substituted alkynyls, aryls and substituted aryls, wherein R2, R3 and R4 are selected such that at least one of R2, R3 and R4 is an acyl.          When R2, R3 and R4 include one or more acyls that are not identical to the acyl of R1, these compounds of formula I are novel compounds.  The invention also includes processes to produce the compounds of formula I.          Compounds of formula I complex and/or chelate tissue tri-valent ions, especially iron and aluminum (Fe+++, Al+++), when administered to a human being, and are therefore useful in therapy in the treatment of diseases in which tissue ion levels in the body have increased or toxic levels.  These iron-related diseases include, for example, thalassemia major, sideroachrestic anemic, Blackfan-Diamond anemia, aplastic anemia, sickle cell anemia, hemolytic anemias and hemosiderosis brought about by multiple blood transfusions including treatment for the anemia accompanying conditions requiring kidney dialysis. Aluminum-related diseases or conditions include Alzheimer&#39;s disease, senile dementia and dialysis encephalopathy.
FIELD: veterinary microbiology. SUBSTANCE: vaccine has an antigen from the strain Chlamydia psittaci-&#34;250&#34; (pathogen inducing abortus in cows). Antigen is inactivated with formaldehyde in the presence of glutaric dialdehyde. Pathogen is grown simultaneously in yolk and allantois envelops of chicken embryos at concentration 15-20 mcg/ml. Pathogen is adsorbed on alumino-potassium alum and emulsified in oil-lanolin mixture. EFFECT: enhanced effectiveness of vaccine, decreased morbidity and death of calves. 4 tbl
The present invention provides systems and methods for conducting electronic transactions in a distributed computing environment. A communications protocol is provided that enables reliable transactional state synchronization for peers participating in a distributed transaction. A transaction processing application is deployed on a local computer system to manage transactions thereon. The local computer system contacts a remote computer system to obtain authorization to execute a transaction. The local computer system initiates a failure-recovery job that is operable to automatically resent status signals and other information to the remote system if the communication with the remote system exhibits certain predefined fault conditions. The remote system is able to dynamically adjust the definition of the predefined fault conditions. If the transaction concludes without triggering the predefined fault conditions, the failure-recovery job is cancelled. The transaction processing application may also allow deferred transactions between remote parties. The transaction processing application maintains a record of the transactions performed by the consumer on the consumer&#39;s local system. Upon the occurrence of predefined conditions, transactional records are sent to a remote vendor or clearinghouse. The vendor or clearinghouse can manage the risk it bears by setting the predefined conditions appropriately. &lt;IMAGE&gt;
The invention relates to an oligonucleotide aptamer APT-1 for specifically recognizing gastric cancer and application thereof, belonging to the technical field of molecular biomedicine. The invention provides an oligonucleotide aptamer APT-1 for specifically recognizing gastric cancer, and the nucleotide sequence of the oligonucleotide aptamer APT-1 is shown as SEQ ID NO. 1. The oligonucleotide aptamer APT-1 is synthesized by in vitro chemical synthesis or biological method, wherein the biological method is preferably PCR. The 5 &#39;end or the 3&#39; end of the oligonucleotide aptamer APT-1 is labeled with one or more of isotope, biotin, digoxin and fluorescent substance/nano material. The aptamer APT-1 has good affinity and specificity to a target, can be used as a detection molecule, and is applied to clinical auxiliary diagnosis, tumor biological guide treatment and the like of a gastric cancer serum specimen. The affinity and specificity of the oligonucleotide aptamer APT-1 to the screening target and the serum of the gastric cancer patient are verified by a q-PCR method and a quantum dot method.